We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-9.4%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.21B
AUM Growth
-$432M
Cap. Flow
-$92.5M
Cap. Flow %
-4.18%
Top 10 Hldgs %
42.68%
Holding
227
New
13
Increased
52
Reduced
76
Closed
10

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$14.4M
2
CNC icon
Centene
CNC
+$8.41M
3
SNY icon
Sanofi
SNY
+$6.73M
4
LLY icon
Eli Lilly
LLY
+$6.66M
5
IQV icon
IQVIA
IQV
+$6.64M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$15.5M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$12.5M
3
JNJ icon
Johnson & Johnson
JNJ
+$11.1M
4
MDCO
Medicines Co
MDCO
+$10.3M
5
ELV icon
Elevance Health
ELV
+$9.94M

Sector Composition

Rank Sector Weight
1 Healthcare 95.66%
2 Real Estate 2.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN
151
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$1.54M 0.07%
45,164
+16,039
+55% +$733K
PACB icon
152
Pacific Biosciences
PACB
$404M
$1.52M 0.07%
495,495
– –
ITCI
153
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$1.45M 0.07%
94,238
– –
THC icon
154
Tenet Healthcare
THC
$21.1B
$1.39M 0.06%
96,736
-16,700
-15% -$479K
MEDP icon
155
Medpace
MEDP
$16.4B
$1.39M 0.06%
18,871
– –
HQY icon
156
HealthEquity
HQY
$8.73B
$1.38M 0.06%
27,310
-4,500
-14% -$299K
EXAS
157
DELISTED
Exact Sciences
EXAS
$1.34M 0.06%
+23,133
New +$1.88M
AUPH icon
158
Aurinia Pharmaceuticals
AUPH
$1.95B
$1.32M 0.06%
90,788
– –
ESPR
159
DELISTED
Esperion Therapeutics
ESPR
$1.31M 0.06%
41,577
-171,985
-81% -$9.08M
DHC
160
Diversified Healthcare Trust
DHC
$2.22B
$1.3M 0.06%
357,720
– –
LKFT
161
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.71B
$1.28M 0.06%
6,543
– –
RVNC
162
DELISTED
Revance Therapeutics, Inc.
RVNC
$1.27M 0.06%
85,840
– –
HALO icon
163
Halozyme
HALO
$9.91B
$1.26M 0.06%
+69,917
New +$1.33M
EVH icon
164
Evolent Health
EVH
$346M
$1.25M 0.06%
231,027
– –
WVE icon
165
Wave Life Sciences
WVE
$1.17B
$1.2M 0.05%
128,146
+28,134
+28% +$240K
ACIU icon
166
AC Immune
ACIU
$233M
$1.19M 0.05%
171,813
– –
ARNA
167
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.18M 0.05%
28,002
– –
TECX
168
Tectonic Therapeutic
TECX
$558M
$1.17M 0.05%
6,240
– –
HOLX
169
DELISTED
Hologic
HOLX
$1.14M 0.05%
32,564
-10,137
-24% -$483K
BBIO icon
170
BridgeBio Pharma
BBIO
$16.1B
$1.14M 0.05%
39,228
– –
UHT
171
Universal Health Realty Income Trust
UHT
$589M
$1.14M 0.05%
11,258
+5,516
+96% +$608K
OVID icon
172
Ovid Therapeutics
OVID
$489M
$1.11M 0.05%
372,733
– –
KOD icon
173
Kodiak Sciences
KOD
$2.73B
$1.1M 0.05%
+23,153
New +$1.39M
VRNA
174
DELISTED
Verona Pharma
VRNA
$1.04M 0.05%
253,179
-21,821
-8% -$120K
QTNT
175
DELISTED
Quotient Limited Ordinary Shares
QTNT
$1.03M 0.05%
6,501
– –
5 6
7
8 9

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2020 Portfolio in Review

As of Q1 2020, Tekla Capital Management held 227 positions worth $2.21B, down 16% from $2.64B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Tekla Capital Management withdrew a net $92.5M in Q1 2020, closing 10 positions and reducing 76 holdings. Its most notable exit was Medicines Co, an estimated $10.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Real Estate.

Against the trend, Tekla Capital Management opened a new position in Moderna worth $7.61M.

  • Tekla Capital Management's largest Q1 2020 buy was Moderna: 254,146 shares worth $7.61M.
  • Tekla Capital Management added most to Biogen in Q1 2020, an estimated $14.4M increase.
  • Tekla Capital Management's biggest Q1 2020 reduction was Merck, cutting an estimated $15.5M.
  • Tekla Capital Management fully exited Medicines Co in Q1 2020, selling an estimated $10.3M.
  • Tekla Capital Management's ten largest holdings make up 43% of its $2.21B portfolio in Q1 2020.
  • Tekla Capital Management opened 13 new positions and closed 10 in Q1 2020.
  • Tekla Capital Management's portfolio value fell 16% quarter-over-quarter to $2.21B.

Based on Tekla Capital Management's 13F filing for Q1 2020, filed 14 May 2020.